Evidence map›Paper›PMID 29340073›Full record

ArticleOncotarget2017

YM155 exerts potent cytotoxic activity against quiescent (G

Miyuki Ookura, Tatsuya Fujii, Hideki Yagi, Takuya Ogawa, Shinji Kishi, Naoko Hosono, Hiroko Shigemi, Takahiro Yamauchi, Takanori Ueda, Akira Yoshida

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Miyuki OokuraDepartment of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
Tatsuya FujiiDepartment of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
Hideki YagiDepartment of Pharmaceutical Sciences, International University of Health and Welfare, Otawara, Tochigi 324-8501, Japan.
Takuya OgawaDepartment of Pharmaceutical Sciences, International University of Health and Welfare, Otawara, Tochigi 324-8501, Japan.
Shinji KishiDepartment of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
Naoko HosonoDepartment of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
Hiroko ShigemiDepartment of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
Takahiro YamauchiDepartment of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
Takanori UedaDepartment of Hematology and Oncology, University of Fukui, Matsuoka, Fukui 910-1193, Japan.
Akira YoshidaDepartment of Hematology, International University of Health and Welfare Hospital, Iguchi, Nasushiobara, Tochigi, 329-2763, Japan.
University of Fukui · JPInternational University of Health and Welfare · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

YM155, a novel small molecule inhibitor of survivin, shows broad anticancer activity. Here, we have focused on the cytotoxic activity of YM155 against multiple myeloma (MM) including cytokinetically quiescent (G

Indexed as

Mcl-1multiple myelomaquiescent cellssurvivinYM155

Identifiers

PMID29340073
PMCPMC5762341
OpenAlexW2771875454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.